Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.64
NSPR's Cash to Debt is ranked higher than
67% of the 518 Companies
in the Global Medical Devices industry.

( Industry Median: 2.03 vs. NSPR: 1.64 )
NSPR' s 10-Year Cash to Debt Range
Min: 0.34   Max: No Debt
Current: 1.64

Equity to Asset 0.30
NSPR's Equity to Asset is ranked lower than
52% of the 477 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. NSPR: 0.30 )
NSPR' s 10-Year Equity to Asset Range
Min: -0.65   Max: 0.78
Current: 0.3

-0.65
0.78
F-Score: 3
Z-Score: -11.58
M-Score: -8.68
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -1271.54
NSPR's Operating margin (%) is ranked lower than
55% of the 492 Companies
in the Global Medical Devices industry.

( Industry Median: 5.14 vs. NSPR: -1271.54 )
NSPR' s 10-Year Operating margin (%) Range
Min: -840.95   Max: -228.66
Current: -1271.54

-840.95
-228.66
Net-margin (%) -1342.47
NSPR's Net-margin (%) is ranked lower than
55% of the 492 Companies
in the Global Medical Devices industry.

( Industry Median: 3.47 vs. NSPR: -1342.47 )
NSPR' s 10-Year Net-margin (%) Range
Min: -890.53   Max: -244.25
Current: -1342.47

-890.53
-244.25
ROE (%) -376.94
NSPR's ROE (%) is ranked lower than
57% of the 486 Companies
in the Global Medical Devices industry.

( Industry Median: 4.76 vs. NSPR: -376.94 )
NSPR' s 10-Year ROE (%) Range
Min: -434.39   Max: -256.02
Current: -376.94

-434.39
-256.02
ROA (%) -167.77
NSPR's ROA (%) is ranked lower than
57% of the 520 Companies
in the Global Medical Devices industry.

( Industry Median: 1.86 vs. NSPR: -167.77 )
NSPR' s 10-Year ROA (%) Range
Min: -436.36   Max: -155.85
Current: -167.77

-436.36
-155.85
ROC (Joel Greenblatt) (%) -3683.76
NSPR's ROC (Joel Greenblatt) (%) is ranked lower than
55% of the 515 Companies
in the Global Medical Devices industry.

( Industry Median: 7.57 vs. NSPR: -3683.76 )
NSPR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3904.12   Max: -1255.56
Current: -3683.76

-3904.12
-1255.56
» NSPR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

NSPR Guru Trades in

NSPR Guru Trades in

NSPR Guru Trades in

Q1 2015

NSPR Guru Trades in Q1 2015

Jim Simons 65,900 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with NSPR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.40
NSPR's P/B is ranked higher than
71% of the 580 Companies
in the Global Medical Devices industry.

( Industry Median: 3.92 vs. NSPR: 3.40 )
NSPR' s 10-Year P/B Range
Min: 2.87   Max: 420
Current: 3.4

2.87
420
P/S 4.80
NSPR's P/S is ranked higher than
56% of the 580 Companies
in the Global Medical Devices industry.

( Industry Median: 4.21 vs. NSPR: 4.80 )
NSPR' s 10-Year P/S Range
Min: 4.02   Max: 98.18
Current: 4.8

4.02
98.18
EV-to-EBIT -0.59
NSPR's EV-to-EBIT is ranked lower than
61% of the 580 Companies
in the Global Medical Devices industry.

( Industry Median: 259.85 vs. NSPR: -0.59 )
NSPR' s 10-Year EV-to-EBIT Range
Min: -49.4   Max: -0.2
Current: -0.59

-49.4
-0.2
Current Ratio 2.14
NSPR's Current Ratio is ranked higher than
65% of the 514 Companies
in the Global Medical Devices industry.

( Industry Median: 2.67 vs. NSPR: 2.14 )
NSPR' s 10-Year Current Ratio Range
Min: 0.13   Max: 4.68
Current: 2.14

0.13
4.68
Quick Ratio 1.91
NSPR's Quick Ratio is ranked higher than
69% of the 514 Companies
in the Global Medical Devices industry.

( Industry Median: 1.95 vs. NSPR: 1.91 )
NSPR' s 10-Year Quick Ratio Range
Min: 0.13   Max: 4.28
Current: 1.91

0.13
4.28
Days Inventory 311.78
NSPR's Days Inventory is ranked higher than
60% of the 580 Companies
in the Global Medical Devices industry.

( Industry Median: 172.71 vs. NSPR: 311.78 )
NSPR' s 10-Year Days Inventory Range
Min: 131.59   Max: 315.56
Current: 311.78

131.59
315.56
Days Sales Outstanding 200.72
NSPR's Days Sales Outstanding is ranked higher than
58% of the 580 Companies
in the Global Medical Devices industry.

( Industry Median: 84.05 vs. NSPR: 200.72 )
NSPR' s 10-Year Days Sales Outstanding Range
Min: 82.25   Max: 138.85
Current: 200.72

82.25
138.85

Valuation & Return

vs
industry
vs
history
Price/Net Cash 24.00
NSPR's Price/Net Cash is ranked higher than
83% of the 580 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. NSPR: 24.00 )
NSPR' s 10-Year Price/Net Cash Range
Min: 7.37   Max: 109
Current: 24

7.37
109
Price/Net Current Asset Value 8.00
NSPR's Price/Net Current Asset Value is ranked higher than
85% of the 580 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. NSPR: 8.00 )
NSPR' s 10-Year Price/Net Current Asset Value Range
Min: 5.26   Max: 76.25
Current: 8

5.26
76.25
Price/Tangible Book 3.40
NSPR's Price/Tangible Book is ranked higher than
78% of the 580 Companies
in the Global Medical Devices industry.

( Industry Median: 7.90 vs. NSPR: 3.40 )
NSPR' s 10-Year Price/Tangible Book Range
Min: 4.6   Max: 390
Current: 3.4

4.6
390
Price/Median PS Value 0.30
NSPR's Price/Median PS Value is ranked higher than
98% of the 580 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. NSPR: 0.30 )
NSPR' s 10-Year Price/Median PS Value Range
Min: 0.36   Max: 5.16
Current: 0.3

0.36
5.16
Earnings Yield (Greenblatt) -169.50
NSPR's Earnings Yield (Greenblatt) is ranked lower than
64% of the 505 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. NSPR: -169.50 )
NSPR' s 10-Year Earnings Yield (Greenblatt) Range
Min: -169.5   Max: 0
Current: -169.5

-169.5
0

Business Description

Industry: Medical Devices » Medical Devices
Compare: » details
InspireMD Inc was organized in the State of Delaware on February 29, 2008 as Saguaro Resources, Inc. On March 28, 2011, it effectuated a 1-for-3 forward stock split and changed its name from Saguaro Resources, Inc. to InspireMD, Inc. It is an medical device company focusing on the development and commercialization of its proprietary stent platform technology, MGuard. MGuard provides embolic protection in stenting procedures by placing a micron mesh sleeve over a stent. The Company's initial products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). According to the TYPHOON STEMI trial and the SOS SVG Trial of patients with acute myocardial infarction and saphenous vein graft coronary interventions, 7.5% to 44% experience adverse cardiac events, including cardiac death, heart attack, and restenting of the artery. When performing stenting procedures in patients with acute coronary symptoms, interventional cardiologists face a difficult dilemma in choosing between bare-metal stents, which have a high rate of restenosis (formation of new blockages), and drug-eluting (drug-coated) stents, which have a high rate of late thrombosis (formation of clots months or years after implantation), require administration of anti-platelet drugs for at least one year post procedure, are more costly than bare-metal stents and have additional side effects. It intends to use its MGuard technology in a broad range of coronary related situations in which complex lesions are required and make it an industry standard for treatment of acute coronary syndromes. It also intends to apply its technology to develop additional products used for other vascular procedures, specifically carotid (the arteries that supply blood to the brain) and peripheral (other arteries) procedures. The Company markets its products through distributers in international markets, mainly in Europe and Latin America.
» More Articles for NSPR

Headlines

Articles On GuruFocus.com
InspireMD Reports 4 Significant Insider Buys Apr 19 2013 

More From Other Websites
8:01 am InspireMD announced that its CGuard Embolic Prevention System reported positive results in... May 25 2015
InspireMD’s CGuard™ Highlighted at Clinical Presentation at EuroPCR 2015 Conference May 22 2015
INSPIREMD, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and... May 22 2015
InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference May 22 2015
INSPIREMD, INC. Financials May 20 2015
InspireMD Announces Completion of Sales Restructuring Program May 14 2015
InspireMD Announces MGuard™ Prime Approval in Brazil May 14 2015
InspireMD Reports Financial Results for the First Quarter Ended March 31, 2015 May 14 2015
InspireMD Announces Clinical Presentations on CGuard™ and MGuard™ Systems with MicroNet™... May 14 2015
INSPIREMD, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 12 2015
InspireMD Announces Clinical Presentations on CGuard and MGuard Systems with MicroNet™ Technology... May 12 2015
INSPIREMD, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 11 2015
InspireMD Reports Financial Results for the First Quarter Ended March 31, 2015 May 11 2015
Q1 2015 InspireMD Inc Earnings Release - Before Market Open May 11 2015
InspireMD to Report Financial Results for the First Quarter Ended March 31, 2015 on Monday, May 11th May 05 2015
3 Stocks Under $10 Making Big Moves Higher Apr 28 2015
INSPIREMD, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 27 2015
InspireMD Announces MGuard™ Prime Approval in Brazil Apr 27 2015
INSPIREMD, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events,... Apr 15 2015
InspireMD Announces Completion of Sales Restructuring Program Apr 15 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK